Science Publishing Group

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Arcadia University Announces New Academic Programs for Fall 2024

Retrieved on: 
Thursday, February 29, 2024
Science Publishing Group, Arcadia University, Public health, Leadership studies, Faculty, News, Behavior, Student, Nursing

Arcadia also is proud to offer, beginning in fall 2024, a minor in Japanese; master's degree programs in Rehabilitation Science and Public Health (4+1 program), and certificates in Health Equity; Social, Emotional, and Behavioral Wellbeing; and Organizational Leadership.

Key Points: 
  • Arcadia also is proud to offer, beginning in fall 2024, a minor in Japanese; master's degree programs in Rehabilitation Science and Public Health (4+1 program), and certificates in Health Equity; Social, Emotional, and Behavioral Wellbeing; and Organizational Leadership.
  • The addition of these academic programs reflects Arcadia's commitment to providing students with a customized education that features interdisciplinary coursework and hands-on learning opportunities.
  • "These upcoming academic programs allow students even more options to earn degrees at Arcadia University, while preparing them for sustained career success," said Jeff Rutenbeck, provost and senior vice president for Academic Affairs at Arcadia University.
  • The programs continue with Arcadia's focus on preparing students for career success: 97 percent of recent Arcadia students secured jobs or graduate program placements within 6 to 9 months of earning their degrees.

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Diabetes, Senior, Medtronic, Doctor of Philosophy, Computer science, Science Publishing Group, Marketing, US FDA, Growth, MBA, University, Mathematics, Engineering, Software engineering, Fresenius (company), Medtech, Patient, Development, Korea Exchange, Management

“I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack,” said Andrew Sycoff, member of the Board of Directors.

Key Points: 
  • “I can think of no better person to lead our Board during this exciting and pivotal time for Glucotrack,” said Andrew Sycoff, member of the Board of Directors.
  • “I am honored to take on this important role,” said Mr. Malavé, who has served on the Glucotrack Board since 2021.
  • “Glucotrack has an innovative and compelling technology that will address unmet needs and expand patient choice in the diabetes market.
  • He has been an incredible champion of Glucotrack’s vision throughout his entire tenure on our Board,” said Paul V. Goode, PhD, President & CEO of Glucotrack.

Safer Internet Day 2024: Yubo Supports the UK Safer Internet Centre, Joining Forces to Poll UK Gen Z about Emerging Technologies, Online Safety

Retrieved on: 
Tuesday, February 6, 2024
Online, Partnership, Internet, Policy, Parent, Research, Feedback, User experience, Government, Safety, Science Publishing Group, Home, Ageing, Organic, Generation Z, DSIT, Gen, Privacy, Yubo, Department for Education, Childnet, Insafe, Conference, Safer, UKSIC, Online shopping

"Safer Internet Day provides the best opportunity in the year to promote safe and responsible use of technology.

Key Points: 
  • "Safer Internet Day provides the best opportunity in the year to promote safe and responsible use of technology.
  • UKSIC's Safer Internet Day 2024 research generated similar findings to the poll conducted among Yubo users.
  • The UK Safer Internet Centre will host today the Safer Internet Day Virtual Youth Conference, from 1:30 p.m. to 3 p.m. GMT.
  • The results of the Yubo-UK Safer Internet Centre Safer Internet Day 2024 poll can be accessed via the Yubo blog .

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Probability, Microbiome, Emperor, Harvard Medical School, National academy, Computational biology, Genetic engineering, Inflammatory bowel disease, University, Infection, Biological engineering, Therapy, Synthetic biology, DNA, Harvard University, Biostatistics, Biomedical engineering, MIT, Disease, NIH, Science Publishing Group, MacArthur Fellows Program, Metabolism, Wyss Institute, Entrepreneurship, Artificial intelligence, Cell growth, Distinguishing, Immunology, SAB, Dysbiosis, Microbiota, Biology, Dana–Farber Cancer Institute, Huntsman Cancer Institute, Mass spectrometry, Princeton University, Genomics, Public health, Protein, Diabetes, Pharmaceutical industry

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

BostonGene Announces Publication in Blood

Retrieved on: 
Wednesday, December 20, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Bone marrow, Science Publishing Group, Pathology, Haematopoiesis, Weill Cornell Medicine, Medical laboratory, Ageing, Assistant, Manuscript, Hematology, MPH, Diagnosis, Medical imaging

BostonGene , a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “ Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling ,” in Blood, the most cited peer-reviewed publication in the field of hematology.

Key Points: 
  • BostonGene , a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “ Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling ,” in Blood, the most cited peer-reviewed publication in the field of hematology.
  • In a recent collaboration, Sanjay Patel, MD, MPH, Assistant Professor of Pathology and Laboratory Medicine and Director of the Multiparametric In Situ Imaging Laboratory at Weill Cornell Medicine, collaborated with BostonGene to investigate how we look at bone marrow.
  • Historically, limited imaging studies have been performed on bone marrow tissue due to sample heterogeneity and complex analytics.
  • "This adaptable pipeline can be harnessed by other investigators pursuing single-cell resolution spatial investigation of bone marrow,” added Nathan Fowler, MD, Chief Medical Officer at BostonGene.

The Inner Circle Acknowledges, Jerry P. George, MD, FAAD, FACEP as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Retrieved on: 
Monday, December 4, 2023
Johns Hopkins University, Inner circle, Emergency, Children's Medical Center Plano, American Academy, Medical specialty, ABP, Patient, Multimedia, Medicine, Fellow, American College, Biomolecular engineering, Emergency department, Pediatric emergency medicine, St. George's University, SUNY Downstate Medical Center, University, FACEP, Medical City, MSE, Parent, American Board of Pediatrics, Science Publishing Group, Injury, Health, Pediatrics (journal), Emergency medicine, FAAD, Nursing, Pediatrics, Science, Child, Chemical substance, MD, Engineering

DALLAS, Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jerry P. George, MD, FAAD, FACEP, is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • DALLAS, Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jerry P. George, MD, FAAD, FACEP, is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • The doctor followed these accomplishments at St. George's University where he graduated with his Doctor of Medicine (MD) degree in 2012.
  • Dr. George completed a residency at SUNY Downstate Medical Center and remained there until 2015.
  • The doctor currently works in the Emergency Room at Children's Medical Center Plano and Medical City Dallas.

Mary Kay Ash Foundation℠ Awards $2.4 Million in Cancer Research and Domestic Violence Shelter Grants

Retrieved on: 
Tuesday, October 3, 2023
Cosmetics, Retail, Health, Family, Consumer, Other Philanthropy, Philanthropy, Oncology, Mental Health, General Health, Fund Raising, Foundation, Women, Fashion, Medical laboratory, Obstetrics, Science Publishing Group, Senior counsel, Obstetrics and gynaecology, Domestic violence, University, Woman, Prognosis, Multimedia, Research, Associate, Assistant, Weill Cornell Medicine, Pathology, Brown University, Cancer, Gynaecology, Cornell University, Breast cancer, Nursing, Pharmaceutical industry

In celebration of Mary Kay Inc’s 60th anniversary, the Mary Kay Ash Foundation℠ is honored to announce $2.4 million in cancer research and domestic violence shelter grants around the country.

Key Points: 
  • In celebration of Mary Kay Inc’s 60th anniversary, the Mary Kay Ash Foundation℠ is honored to announce $2.4 million in cancer research and domestic violence shelter grants around the country.
  • Established in 1996, the Mary Kay Ash Foundation remains committed to its two-fold mission: cancers affecting women and ending domestic violence.
  • View the full release here: https://www.businesswire.com/news/home/20231003355875/en/
    The Mary Kay Ash Foundation is committed to finding cures for cancers affecting women and ending domestic violence.
  • (Graphic: Mary Kay Ash Foundation)
    This year, 60 domestic violence shelters around the country were awarded $20,000 grants, totaling $1.2 million.

STOPTOBER: Nearly 6 in 10 British Doctors Mistakenly Believe Nicotine Causes Lung Cancer, Endangering Efforts to Help More Than Six Million Brits Quit

Retrieved on: 
Tuesday, October 3, 2023
Smoke, COPD, Learning, Smoker, Smoking, Nicotine, Hereditary diffuse gastric cancer, Doctor, Cancer, Lung cancer, Herbal cigarette, Bladder cancer, Head, Neck, Atherosclerosis, UK Government Decontamination Service, Government, Science Publishing Group, Patient, Physician, NHS, Death, Tobacco, Nursing, Health

LONDON, Oct. 3, 2023 /PRNewswire/ -- Nearly 6 in 10 doctors in the UK mistakenly attribute negative health consequences of smoking to nicotine, directly jeopardising efforts made in helping smokers quit, a survey funded by a Foundation for a Smoke-Free World grant has found.

Key Points: 
  • 60% of British doctors on average incorrectly believe nicotine causes both lung cancer and 65% believe it causes atherosclerosis.
  • 1 in 2 UK doctors says they are not appropriately trained to help patients quit smoking.
  • The misconception about the dangers of nicotine among British doctors leaves 60% believing it directly causes lung cancer.
  • A similar number (59%) mistakenly believe nicotine causes head, neck, and gastric cancers and 56% say it causes bladder cancer.

Nearly 7 in 10 American Doctors Mistakenly Believe Nicotine Causes Lung Cancer, Thwarting Efforts to Help The Country's More Than 50 Million Smokers Quit

Retrieved on: 
Wednesday, September 20, 2023
Smoke, COPD, Smoker, Nicotine, Doctor, Lung cancer, Bladder cancer, Research, Atherosclerosis, Lung, Science Publishing Group, RRC, Foundation for a Smoke-Free World, Patient, Physician, Heated tobacco product, Birth, Smoking, Smoking cessation, Tobacco, Nursing, Pharmaceutical industry, Health

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Nearly 7 in 10 U.S. doctors mistakenly attribute the negative health consequences of smoking to nicotine, directly jeopardizing advancements made in helping smokers quit, a survey funded by a Foundation for a Smoke-Free World grant has found.

Key Points: 
  • On average, 67% of U.S. doctors mistakenly believe nicotine causes lung cancer and 66%-75% mistakenly believe nicotine is a direct cause of a range of illness such as atherosclerosis, birth defects and more.
  • 93% of doctors in the U.S. at least moderately agree that helping patients quit smoking is a priority.
  • Encouragingly, 81% of American physicians surveyed are at least moderately interested in additional cessation and tobacco harm reduction training.
  • These results raise concerns about U.S. doctors' ability to equip patients who smoke with the most accurate and effective advice on how to quit.